Bioshares Report stated"to date no serious adverse events related to the treatment have been reported in the ANP Phase 2 trial.If the trial results are good then ANP will activate licensing discussions with potential partners"
This report was released just after the Interim results re Acromegaly.
Well here we are.as many have said that anp already have the report. Pfizer will protect their market share.(somavert)
I cannot see Anp selling the whole company for under a $1.
ANP Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
